JP2022535458A - Ｂ型肝炎ウイルス特異的なｔ細胞応答 - Google Patents

Ｂ型肝炎ウイルス特異的なｔ細胞応答 Download PDF

Info

Publication number
JP2022535458A
JP2022535458A JP2021572596A JP2021572596A JP2022535458A JP 2022535458 A JP2022535458 A JP 2022535458A JP 2021572596 A JP2021572596 A JP 2021572596A JP 2021572596 A JP2021572596 A JP 2021572596A JP 2022535458 A JP2022535458 A JP 2022535458A
Authority
JP
Japan
Prior art keywords
protein
active
mhc
hbv
cmv vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535458A5 (https=
Inventor
ジェイ． フルー、クラウス
ジェイ． ピッカー、ルイス
ジェイ． ブルビッツ、ベンジャミン
ジー． ハンセン、スコット
ビー． サチャ、ジョナー
Original Assignee
オレゴン ヘルス アンド サイエンス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ヘルス アンド サイエンス ユニバーシティ filed Critical オレゴン ヘルス アンド サイエンス ユニバーシティ
Publication of JP2022535458A publication Critical patent/JP2022535458A/ja
Publication of JP2022535458A5 publication Critical patent/JP2022535458A5/ja
Priority to JP2025076176A priority Critical patent/JP2025118754A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021572596A 2019-06-07 2020-06-05 Ｂ型肝炎ウイルス特異的なｔ細胞応答 Pending JP2022535458A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076176A JP2025118754A (ja) 2019-06-07 2025-05-01 Ｂ型肝炎ウイルス特異的なｔ細胞応答

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858764P 2019-06-07 2019-06-07
US62/858,764 2019-06-07
PCT/US2020/036480 WO2020247858A1 (en) 2019-06-07 2020-06-05 Hepatitis b virus-specific t cell responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076176A Division JP2025118754A (ja) 2019-06-07 2025-05-01 Ｂ型肝炎ウイルス特異的なｔ細胞応答

Publications (2)

Publication Number Publication Date
JP2022535458A true JP2022535458A (ja) 2022-08-08
JP2022535458A5 JP2022535458A5 (https=) 2023-06-01

Family

ID=73653370

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572596A Pending JP2022535458A (ja) 2019-06-07 2020-06-05 Ｂ型肝炎ウイルス特異的なｔ細胞応答
JP2025076176A Pending JP2025118754A (ja) 2019-06-07 2025-05-01 Ｂ型肝炎ウイルス特異的なｔ細胞応答

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076176A Pending JP2025118754A (ja) 2019-06-07 2025-05-01 Ｂ型肝炎ウイルス特異的なｔ細胞応答

Country Status (5)

Country Link
US (1) US12599658B2 (https=)
EP (1) EP3980061A4 (https=)
JP (2) JP2022535458A (https=)
CN (1) CN113950334B (https=)
WO (1) WO2020247858A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980061A4 (en) 2019-06-07 2023-07-19 Oregon Health & Science University HEPATITIS B VIRUS SPECIFIC T LYMPHOCYTE RESPONSES
MX2022002270A (es) * 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
US20180133321A1 (en) * 2016-10-18 2018-05-17 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6417324B1 (en) 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US20020069244A1 (en) 1999-11-24 2002-06-06 John Blair Message delivery system billing method and apparatus
US20140014103A1 (en) 2012-07-12 2014-01-16 The Research Foundation Of State University Of New York Methods, Devices and Formulations for Targeted Endobronchial Therapy
WO2008039148A1 (en) 2006-09-28 2008-04-03 Packetfront Sweden Ab Method for automatically providing a customer equipment with the correct service
TWI403247B (zh) 2008-07-18 2013-07-21 Delta Electronics Inc 具把手結構之抽取式電子裝置
JP2013112651A (ja) 2011-11-29 2013-06-10 Niigata Beer Co Ltd トリュフ抽出物を含有したｄｈｅａ産生促進剤及びその用途
FR2993576B1 (fr) 2012-07-20 2018-05-18 Nanoplas Dispositif de traitement d'un objet par plasma
US9603790B2 (en) 2012-11-15 2017-03-28 Basf Corporation Cosmetic compositions comprising marine plants
WO2014135209A1 (en) 2013-03-06 2014-09-12 SiEVA Apparatus for high side transistor bridge driver
EP3980061A4 (en) 2019-06-07 2023-07-19 Oregon Health & Science University HEPATITIS B VIRUS SPECIFIC T LYMPHOCYTE RESPONSES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
US20180133321A1 (en) * 2016-10-18 2018-05-17 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY, vol. 121, JPN6024016050, 2007, pages 105 - 112, ISSN: 0005314034 *
J IMMUNOLOGY, vol. 204, JPN6024016051, 2020, pages 2169 - 2176, ISSN: 0005314035 *

Also Published As

Publication number Publication date
CN113950334B (zh) 2025-01-28
WO2020247858A1 (en) 2020-12-10
US12599658B2 (en) 2026-04-14
JP2025118754A (ja) 2025-08-13
EP3980061A4 (en) 2023-07-19
EP3980061A1 (en) 2022-04-13
US20220257748A1 (en) 2022-08-18
CN113950334A (zh) 2022-01-18

Similar Documents

Publication Publication Date Title
US11305015B2 (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
JP6816031B2 (ja) 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
US20200368333A1 (en) Cmv vectors comprising microrna recognition elements
JP2025118754A (ja) Ｂ型肝炎ウイルス特異的なｔ細胞応答
AU2022339765A1 (en) Recombinant hcmv vectors and uses thereof
JP7693651B2 (ja) ヒトサイトメガロウイルスのｕｌ１８によるｔ細胞応答の調節
HK40011160A (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
OA19584A (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
HK1260171A1 (en) Cmv vectors comprising microrna recognition elements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107